Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
study ends around
Principal Investigator
by Juan M Gonzalez Velez, MD PhD

Description

Summary

This pilot study tests the feasibility of conducting an interventional study in pregnant people with chronic hypertension with interventional clinical management based on sFlt-1/PlGF. It will also collect data on time to delivery, the incidence of preterm delivery, and other maternal or neonatal complications, for a pivotal trial.

Official Title

Decreasing Intervention Using sFlt-1/PlGF Applied to Chronic Hypertension (DISPATCH Trial): A Pilot, Open-label, Randomized Controlled Trial

Details

Participants with chronic hypertension between 23+0 and 34+6 weeks presenting to triage for rule out superimposed preeclampsia. They will be randomly assigned to two groups at a 1:1 ratio, conceal or reveal, and will be tested with the sFlt-1/PlGF assay. In the conceal group, participants will have their blood tested but the results will not be returned to the participants or their clinical providers, and thus the participants will continue to receive routine clinical care in pregnancy. In the reveal group, the clinical team will be notified of the assay results (PlGF and sFlt-1 concentrations and ratio) and result status (normal <40 or abnormal using the cut-off ≥40) and will be encouraged to discharge patients with a normal result. The ultimate decision to admit or discharge will still be based on the decision making of the clinical team; if a patient with a normal result is admitted and/or delivered, the clinical team will be asked to record the reason(s) behind the decision(s). Repeat PlGF and sFlt-1 concentration and ratio testing will occur for participants who re-present to triage ≥7 days from the prior test, and on a weekly basis for participants who are admitted. For participants in the reveal group who have had an abnormal result, additional concentration and ratio testing will be performed but results will not be reported to the clinical team.

Keywords

Preeclampsia, Chronic Hypertension Complicating Pregnancy, Pregnancy, sflt/plgf, chronic hypertension, Pre-Eclampsia, sFlt/PlGF lab assay with change in clinical care, sFlt/PlGF without change in clinical care

Eligibility

You can join if…

Open to females ages 18 years and up

  • Age 18 and older
  • Singleton living pregnancy
  • Gestational age between 23+0 and 34+6 weeks gestation, confirmed by a fetal crown-rump length measurement in a first trimester ultrasound or by in vitro fertilization dates
  • Chronic hypertension, defined as:
    • At least 2 blood pressure measurements 140 systolic or 90 diastolic 4 hours apart diagnosed at less than 20 weeks 0 days of gestation and within 12 months of conception.
    • History or current use of anti-hypertensive medications for the indication of lowering blood pressure within 12 months prior to conception or prior to 20 weeks 0 days in the current pregnancy. Use during a prior pregnancy and through 12 weeks postpartum, or use for stage 1 chronic hypertension are not exclusions.
  • Evaluated in triage for worsening chronic hypertension, rule out preeclampsia due to:
    • Worsening blood pressures from baseline and/or development of severe range blood pressures
    • Preeclampsia associated symptoms: headache, vision changes, abdominal pain
    • New onset proteinuria or worsening proteinuria
    • Lab abnormalities suspicious for preeclampsia including anemia, signs of hemolysis, thrombocytopenia, increasing serum creatinine, elevated liver function tests
    • Any other concerning features of preeclampsia according to the evaluating clinician

You CAN'T join if...

  • Hemolysis, elevated liver enzymes, low platelet syndrome (HELLP syndrome), pulmonary edema, eclamptic seizure, stroke, myocardial infarction, placental abruption, or heart failure.
  • Absent or reversed end-diastolic flow in the umbilical artery Doppler
  • Unable to consent
  • Major birth defect or chromosomal abnormality that may necessitate preterm birth for other reasons
  • Other pregnancy complication that may necessitate preterm birth (e.g., PPROM)
  • IV Heparin use within 24 hours of the lab draw
  • Exogenous PlGF-2 or PlGF-3 given for therapeutic use at a concentration higher than 100 pg/mL

Location

  • UCSF
    San Francisco California 94158 United States

Lead Scientist at UCSF

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT07936799
Study Type
Interventional
Participants
Expecting 74 study participants
Last Updated